NASDAQ$CLLS
Cellectis SA-ADR · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Cellectis Q2 2025: revenue doubles to $16.7M on AstraZeneca collaboration; net loss $23.7M
Cellectis reported Q2 2025 revenue of $16.7 million, up from $8.1 million in Q2 2024, primarily driven by revenue recognition under its AstraZeneca joint research and collaboration agreement. Total revenues and other income were $18.2 million versus $9.5 million a year ago. The company posted a Q2 net loss of $23.7 million, or $0.24 per share, compared to a $25.3 million loss in Q2 2024. Operating loss narrowed to $9.6 million from $17.2 million on higher collaboration revenue. R&D expenses were $23.1 million, roughly flat YoY. Cash and cash equivalents were $59.8 million at June 30, 2025, with an additional $136.1 million in current financial assets.
- Q2 revenue of $16.7M more than doubled from $8.1M YoY on AstraZeneca JRCA revenue recognition.
- Operating loss narrowed to $9.6M from $17.2M; net loss of $23.7M ($0.24/share) vs $25.3M ($0.28/share) prior year.
- H1 2025 revenue reached $27.4M vs $12.6M in H1 2024; H1 net loss was $41.9M.
- R&D spending of $23.1M in Q2 remained the primary cost driver for the clinical-stage gene-editing platform.
- Cash and equivalents of $59.8M plus $136.1M in current financial assets; company believes resources sufficient for 12+ months.
Headline financials
Revenue & EPS history
Cellectis SA · Revenue · Quarterly
$16.7M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2025
-2.2%
Avg return
Earnings day
-2.0%
Avg return
5 days after
-0.9%
Avg return
30 days after
38%
16 / 42 earnings
Positive
+9.3%
Q1 2022
Best reaction
-16.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +2.7% | +0.3% | -17.6% | |
| Q2 2025 | -16.1% | -13.9% | -12.9% | |
| Q1 2025 | +2.4% | +0.0% | -9.5% | |
| Q4 2024 | -3.9% | +1.6% | +11.6% | |
| Q3 2024 | -1.1% | -1.7% | +5.0% | |
| Q2 2024 | +1.0% | +2.0% | +11.3% | |
| Q1 2024 | -3.5% | -3.9% | -34.0% | |
| Q3 2023 | -16.4% | -12.2% | +0.7% | |
| Q2 2023 | -3.6% | -3.6% | +4.7% | |
| Q1 2023 | +2.2% | -1.6% | +7.0% | |
| Q4 2022 | -3.9% | -4.5% | -4.2% | |
| Q3 2022 | -7.5% | -9.5% | -13.8% | |
| Q2 2022 | +4.2% | +0.6% | +2.1% | |
| Q1 2022 | +9.3% | +20.0% | -2.4% | |
| Q4 2021 | -14.9% | -11.6% | +16.9% | |
| Q3 2021 | -4.8% | -12.7% | -35.8% | |
| Q2 2021 | +7.1% | +5.3% | +14.3% | |
| Q1 2021 | -3.8% | -6.3% | -14.2% | |
| Q4 2020 | -9.7% | +7.5% | -2.0% | |
| Q3 2020 | +3.4% | +2.9% | +78.4% | |
| Q2 2020 | -2.0% | +1.4% | -5.6% | |
| Q1 2020 | +2.7% | +7.2% | +15.3% | |
| Q4 2019 | +0.3% | -22.8% | -46.9% | |
| Q3 2019 | +2.8% | +9.3% | +18.2% | |
| Q2 2019 | -1.8% | +0.8% | -5.4% | |
| Q1 2019 | -3.2% | -6.7% | -26.5% | |
| Q4 2018 | +3.7% | +7.0% | +9.0% | |
| Q3 2018 | -5.4% | -14.7% | -26.6% | |
| Q2 2018 | +0.0% | -1.2% | +2.0% | |
| Q1 2018 | -1.1% | -2.9% | +6.6% | |
| Q4 2017 | -7.1% | -1.2% | -11.2% | |
| Q3 2017 | -6.4% | -5.3% | +6.9% | |
| Q2 2017 | -2.3% | -1.9% | +36.0% | |
| Q1 2017 | +1.2% | +2.4% | +0.6% | |
| Q4 2016 | -4.1% | +2.5% | +6.7% | |
| Q3 2016 | -3.3% | +0.3% | -5.3% | |
| Q2 2016 | -3.0% | -5.2% | -13.0% | |
| Q1 2016 | -7.6% | — | — | |
| Q4 2015 | +2.5% | — | — | |
| Q3 2015 | -0.9% | — | — | |
| Q2 2015 | +0.9% | — | — | |
| Q1 2015 | -1.6% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q4 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro